Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1932 1
1938 1
1943 3
1946 1
1947 1
1948 2
1949 2
1950 3
1951 5
1952 3
1953 2
1954 5
1955 2
1956 5
1957 4
1958 2
1959 3
1960 3
1961 14
1962 3
1963 9
1964 8
1965 12
1966 12
1967 17
1968 10
1969 23
1970 10
1971 12
1972 22
1973 25
1974 22
1975 21
1976 26
1977 32
1978 19
1979 17
1980 27
1981 22
1982 30
1983 33
1984 41
1985 35
1986 46
1987 50
1988 44
1989 55
1990 38
1991 54
1992 47
1993 40
1994 72
1995 53
1996 62
1997 57
1998 61
1999 55
2000 59
2001 53
2002 46
2003 63
2004 68
2005 68
2006 55
2007 68
2008 71
2009 61
2010 83
2011 69
2012 82
2013 100
2014 105
2015 98
2016 89
2017 70
2018 69
2019 77
2020 116
2021 119
2022 111
2023 86
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

2,980 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Among authors: walker p. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: walker p. Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1. Leukemia. 2022. PMID: 34974526 Free PMC article. No abstract available.
Snapping Hip Syndrome: A Comprehensive Update.
Walker P, Ellis E, Scofield J, Kongchum T, Sherman WF, Kaye AD. Walker P, et al. Orthop Rev (Pavia). 2021 Jun 22;13(2):25088. doi: 10.52965/001c.25088. eCollection 2021. Orthop Rev (Pavia). 2021. PMID: 34745476 Free PMC article. Review.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Tam CS, et al. Among authors: walker p. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7. Lancet Oncol. 2022. PMID: 35810754 Clinical Trial.
Formulation and Delivery Technologies for mRNA Vaccines.
Zeng C, Zhang C, Walker PG, Dong Y. Zeng C, et al. Among authors: walker pg. Curr Top Microbiol Immunol. 2022;440:71-110. doi: 10.1007/82_2020_217. Curr Top Microbiol Immunol. 2022. PMID: 32483657 Free PMC article.
Improving lung health in low-income and middle-income countries: from challenges to solutions.
Meghji J, Mortimer K, Agusti A, Allwood BW, Asher I, Bateman ED, Bissell K, Bolton CE, Bush A, Celli B, Chiang CY, Cruz AA, Dinh-Xuan AT, El Sony A, Fong KM, Fujiwara PI, Gaga M, Garcia-Marcos L, Halpin DMG, Hurst JR, Jayasooriya S, Kumar A, Lopez-Varela MV, Masekela R, Mbatchou Ngahane BH, Montes de Oca M, Pearce N, Reddel HK, Salvi S, Singh SJ, Varghese C, Vogelmeier CF, Walker P, Zar HJ, Marks GB. Meghji J, et al. Among authors: walker p. Lancet. 2021 Mar 6;397(10277):928-940. doi: 10.1016/S0140-6736(21)00458-X. Epub 2021 Feb 22. Lancet. 2021. PMID: 33631128 Review.
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Shankar B, et al. Among authors: walker p. JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012. JAMA Oncol. 2020. PMID: 33119034 Free PMC article.
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: walker p. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
2,980 results